{
    "organizations": [],
    "uuid": "f9008bb093405e78128b90ebfea8f8be757aa0ed",
    "author": "",
    "url": "https://www.reuters.com/article/brief-nucana-announces-promising-clinica/brief-nucana-announces-promising-clinical-data-on-nuc-1031-as-front-line-treatment-of-advanced-biliary-tract-cancer-idUSFWN1PE14W",
    "ord_in_thread": 0,
    "title": "BRIEF-Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - Nucana Plc:\n* NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARINÂ®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER\n* NUCANA SAYS COMBINATION OF ACELARIN AND CISPLATIN WAS WELL-TOLERATED WITH NO UNEXPECTED ADVERSE EVENTS AND NO DOSE-LIMITING TOXICITIES\n* NUCANA PLC - IN TRIAL, 2 OF 8 PATIENTS RECEIVED ONLY ONE CYCLE OR LESS OF THERAPY DUE TO COMPLICATIONS UNRELATED TO EITHER ACELARIN OR CISPLATIN\n* NUCANA SAYS PLAN TO INITIATE PIVOTAL STUDY OF ACELARIN AND CISPLATIN IN FRONT-LINE ADVANCED BILIARY TRACT CANCER IN 2018\n* NUCANA PLC - ANALYSIS OF PHASE 1B STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER\n* NUCANA-STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN, ACHIEVED HIGH RESPONSE RATES, WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-19T19:43:00.000+02:00",
    "crawled": "2018-01-19T20:09:59.050+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "nucana",
        "plc",
        "nucana",
        "announces",
        "promising",
        "clinical",
        "data",
        "asco",
        "gi",
        "treatment",
        "advanced",
        "biliary",
        "tract",
        "cancer",
        "nucana",
        "say",
        "combination",
        "acelarin",
        "cisplatin",
        "unexpected",
        "adverse",
        "event",
        "toxicity",
        "nucana",
        "plc",
        "trial",
        "patient",
        "received",
        "one",
        "cycle",
        "less",
        "therapy",
        "due",
        "complication",
        "unrelated",
        "either",
        "acelarin",
        "cisplatin",
        "nucana",
        "say",
        "plan",
        "initiate",
        "pivotal",
        "study",
        "acelarin",
        "cisplatin",
        "advanced",
        "biliary",
        "tract",
        "cancer",
        "nucana",
        "plc",
        "analysis",
        "phase",
        "1b",
        "study",
        "showed",
        "acelarin",
        "combined",
        "cisplatin",
        "advanced",
        "biliary",
        "tract",
        "cancer",
        "showed",
        "acelarin",
        "combined",
        "cisplatin",
        "achieved",
        "high",
        "response",
        "rate",
        "advanced",
        "biliary",
        "tract",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}